Aura Biosciences Inc (AURA)
NASDAQ:AURA
Want to see AURA full AI Analyst Report?
AURA Stock Chart & Stats
$7.29
-$0.11(-1.36%)
At close: 4:00 PM EST
$7.29
-$0.11(-1.36%)
Day’s Range― - ―
52-Week Range$4.73 - $9.54
Previous CloseN/A
Volume82.15K
Average Volume (3M)705.10K
Market Cap
$642.03M
Enterprise Value$411.77M
Total Cash (Recent Filing)$114.73M
Total Debt (Recent Filing)$16.99M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Aug 06, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.77
Shares Outstanding103,386,560
10 Day Avg. Volume426,682
30 Day Avg. Volume705,102
Financial Highlights & Ratios
PEG Ratio-5.42
Price to Book (P/B)2.40
Price to Sales (P/S)0.00
P/FCF Ratio-3.86
Enterprise Value/Market Cap0.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-717.37
Enterprise Value/Ebitda-3.70
Forecast
1Y Price Target
$20.67Price Target Upside183.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.6
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Extended Cash RunwayThe $280.8M net proceeds materially strengthen liquidity and provide a multi-year runway into H2 2028. This reduces near-term financing risk, supports uninterrupted Phase 3 execution and registration-enabling work, and allows management to allocate capital strategically without immediate fundraising.
Late-stage Phase 3 ProgramAura’s CoMpass Phase 3 program is nearing enrollment with topline data expected in H2 2027. A positive, timely Phase 3 readout would be a structural value inflection enabling potential regulatory filings and commercialization planning, converting R&D investment into a durable market opportunity.
Modest LeverageLow absolute debt (~$17M) versus equity (~$107.2M) limits interest expense and preserves financial flexibility. Modest leverage supports operational freedom to prioritize clinical development and regulatory activities without heavy debt servicing that could constrain strategic choices during the pre-revenue stage.
Bears Say
No Revenue / Widening LossesAura remains pre-revenue with a TTM net loss of roughly $112.4M, reflecting structural unprofitability. Persistent losses erode equity, increase reliance on external capital, and mean the company must translate clinical success into sustained commercial sales before achieving durable profitability.
Persistent Cash BurnOperating cash flow and free cash flow are deeply negative (~-$91M TTM), indicating ongoing and growing cash burn. This structural cash consumption necessitates regular access to capital markets or dilution and constrains long-term planning absent milestone-driven revenue or material expense reductions.
Clinical And Regulatory Execution RiskAura’s prospects depend on clinical and regulatory outcomes for bel-sar and expansion programs. Development-stage assets carry binary trial and approval risks; adverse results or regulatory delays would materially impair commercialization timelines, revenue potential, and the company’s return on invested capital.
Aura Biosciences Inc News
AURA FAQ
What was Aura Biosciences Inc’s price range in the past 12 months?
Aura Biosciences Inc lowest stock price was $4.73 and its highest was $9.54 in the past 12 months.
What is Aura Biosciences Inc’s market cap?
Aura Biosciences Inc’s market cap is $642.03M.
When is Aura Biosciences Inc’s upcoming earnings report date?
Aura Biosciences Inc’s upcoming earnings report date is Aug 06, 2026 which is in 54 days.
How were Aura Biosciences Inc’s earnings last quarter?
Aura Biosciences Inc released its earnings results on May 11, 2026. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.398 by -$0.102.
Is Aura Biosciences Inc overvalued?
According to Wall Street analysts Aura Biosciences Inc’s price is currently Undervalued.
Does Aura Biosciences Inc pay dividends?
Aura Biosciences Inc does not currently pay dividends.
What is Aura Biosciences Inc’s EPS estimate?
Aura Biosciences Inc’s EPS estimate is -0.38.
How many shares outstanding does Aura Biosciences Inc have?
Aura Biosciences Inc has 103,386,560 shares outstanding.
What happened to Aura Biosciences Inc’s price movement after its last earnings report?
Aura Biosciences Inc reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.398. Following the earnings report the stock price went down -3.175%.
Which hedge fund is a major shareholder of Aura Biosciences Inc?
Currently, no hedge funds are holding shares in AURA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aura Biosciences Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.67 (183.49% Upside)
$20.67 (183.49% Upside)
Blogger Sentiment
Bullish
AURA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 83.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $39.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 3.2%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.33%
12-Months-Change
Fundamentals
Return on Equity
-78.12%
Trailing 12-Months
Asset Growth
-11.41%
Trailing 12-Months
Company Description
Aura Biosciences Inc
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
AURA Stock 12 Month Forecast
Average Price Target
$20.67
▲(183.49% Upside)
Technical Analysis
Assembly Biosciences
―
Korro Bio
―
Annexon Biosciences
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Ownership Overview
2.82% Insiders
5.21% Mutual Funds
33.38% Other Institutional Investors
53.44% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---